title: Chemotherapy for endometrial carcinoma (GOGO-EM1 study): TEC (paclitaxel, epirubicin, and carboplatin) is an effective remission-induction and adjuvant therapy.
abstract: BACKGROUND
  TAP chemotherapy (paclitaxel, doxorubicin, and cisplatin) is effective for advanced and recurrent endometrial carcinoma, but has occasional severe toxicity. TEC chemotherapy (paclitaxel, epirubicin, and carboplatin) has been suggested to have less toxicity; however, the optimal dosage has yet to be determined.
  
  
  METHODS
  Phase I/II prospective study for TEC therapy was performed. A retrospective comparison of the prognosis between adjuvant TEC therapy and radiation for completely resected cases with risk factors was also performed.
  
  
  RESULTS
  The recommended dose of TEC therapy was determined to be paclitaxel 150 mg/m(2), epirubicin 50 mg/m(2), and carboplatin AUC 4. A TEC regimen at this dose level was shown to be tolerable. The response rate and median overall survival were 74% and 37 months for those with advanced primary disease (Group B) and 50% and 26 months for recurrent tumors (Group C), respectively. A retrospective comparison showed that adjuvant TEC therapy for completely resected stage III cases improved their prognosis when compared to an adjuvant radiation therapy.
  
  
  CONCLUSIONS
  TEC therapy was demonstrated to be a tolerable and effective treatment, not only as a remission-induction therapy for advanced and recurrent endometrial carcinomas but also as the adjuvant therapy.
authors.affiliation: Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
authors.forename: Tomomi
authors.initials: T
authors.lastname: Egawa-Takata
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Ueda
authors.forename: Chie
authors.initials: C
authors.lastname: Kuragaki
authors.forename: Takahito
authors.initials: T
authors.lastname: Miyake
authors.forename: Takashi
authors.initials: T
authors.lastname: Miyatake
authors.forename: Masami
authors.initials: M
authors.lastname: Fujita
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Yoshino
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Nakashima
authors.forename: Mika
authors.initials: M
authors.lastname: Okazawa
authors.forename: Tateki
authors.initials: T
authors.lastname: Tsutsui
authors.forename: Ken-Ichirou
authors.initials: K
authors.lastname: Morishige
authors.forename: Tadashi
authors.initials: T
authors.lastname: Kimura
authors.forename: Masato
authors.initials: M
authors.lastname: Yamasaki
authors.forename: Takamichi
authors.initials: T
authors.lastname: Nishizaki
authors.forename: Masaaki
authors.initials: M
authors.lastname: Nagamatsu
authors.forename: Kimihiko
authors.initials: K
authors.lastname: Ito
authors.forename: Masahiro
authors.initials: M
authors.lastname: Asada
authors.forename: Kazuhide
authors.initials: K
authors.lastname: Ogita
authors.forename: Akinori
authors.initials: A
authors.lastname: Wakimoto
authors.forename: Toshiya
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Nishio
authors.forename: Takayuki
authors.initials: T
authors.lastname: Enomoto
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D012189:Retrospective Studies
chemical_list: D015251:Epirubicin; D016190:Carboplatin; D017239:Paclitaxel